Altogen Labs

Austin, United States Founded: 2008 • Age: 18 yrs
Offers xenograft models, toxicology testing, and stable cell line development for drug research.

About Altogen Labs

Altogen Labs is a Healthcare company based in Austin (United States) founded in 2008 by Dmitriy Ovcharenko. It offers xenograft models, toxicology testing, and stable cell line development for drug research. It operates on a B2B model. Its chief executive, as recorded, is Dmitriy Ovcharenko. Its website altogenlabs.com draws about 14 thousand monthly visits. Altogen Labs offers products and services including Xenograft Models, Stable Cell Lines, In Vivo siRNA Delivery, and Toxicology Testing. Its focus areas include Biotechnology, Preclinical Research, Xenograft Models and Toxicology Testing. Similar companies include Dicerna Pharmaceuticals, Rejuvenate Bio and Orna; 3 of its 3 listed similar companies have raised funding.

Company details

Altogen Labs, based in Austin, Texas, is a GLP-compliant laboratory specializing in preclinical research services. They provide xenograft animal models, pharmacology testing, and in vivo toxicology studies for pharmaceutical and academic clients. Services include stable cell line generation, RNAi delivery, and assay development to support drug efficacy and safety evaluations. The company conducts experiments using immunocompromised mice and offers detailed data reporting, focusing on cancer research and biotechnology applications.

  • Headquarters Austin, United States
  • Founders Dmitriy Ovcharenko
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website altogenlabs.com
  • Social LinkedIn X Facebook YouTube

Products & Services of Altogen Labs

Altogen Labs offers a comprehensive portfolio of products and services, including Xenograft Models, Stable Cell Lines, In Vivo siRNA Delivery, and Toxicology Testing.

Xenograft Models
Preclinical Services

Provides animal models for cancer research and drug testing.

Stable Cell Lines
Cell Biology

Develops cell lines for gene expression and drug screening studies.

In Vivo siRNA Delivery
RNAi Services

Offers targeted RNA interference for therapeutic research.

Toxicology Testing
Safety Services

Conducts toxicity assessments for drug development.

Apps and channels of Altogen Labs

its YouTube channel Altogen Labs has 1.75K subscribers and 30 videos.

Altogen Labs
YouTube 1.75K subscribers 30 videos Science & Technology
Open channel

Videos from Altogen Labs

The most watched videos on Altogen Labs's YouTube channel, Altogen Labs (1.75K subscribers). Click a video to play it here.

Altogen Labs | Efficacy and Safety Preclinical Services to Accelerate Research Needs | Biology CRO
2.6K views
Liposome encapsulation services | Altogen Labs
2.2K views
Targeted siRNA qPCR Assays
2K views
MDA-MB-231 Xenograft Model
1.4K views

More on Altogen Labs.

People of Altogen Labs

1 people are tracked at Altogen Labs (1 in leadership).

NameRoleGroup
Dmitriy Ovcharenko
Founder, CEOLeadership
Premium access

Complete people profiles for Altogen Labs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Similar companies to Altogen Labs

Altogen Labs has 3 listed similar companies in our database, 3 of them funded. They include Dicerna Pharmaceuticals, Rejuvenate Bio and Orna.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
dicerna.com2007Lexington, United States$106.45M337
Drugs are developed using RNA interference technology platform.
rejuvenatebio.com2017San Diego, United States$14.58M39
Gene-editing platform and anti-aging therapy for dogs are developed.
ornatx.com2020Cambridge, United States$201M113
Technologies for producing circular RNA therapeutics are developed.
Premium access

Detailed similar companies of Altogen Labs

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Altogen Labs

The website of Altogen Labs (altogenlabs.com) receives about 14K visits a month.

  • Monthly visits
    14K

    ▼ 2.1% vs previous month

Similar websites

Websites whose visitors overlap most with Altogen Labs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
biocytogen.com
100%
23.6K#1,249,047View details
reactionbiology.com
94%
15.6K#1,617,891View details
cofactorgenomics.com
83%
4.2K#4,572,217View details
cellecta.com
72%
16.5K#1,583,800View details
taconic.com
65%
49.8K#707,498View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 6 similar websites and full traffic analytics for Altogen Labs

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 6 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Altogen Labs (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Altogen Labs

Premium access

Complete news archive for Altogen Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Altogen Labs

Altogen Labs was founded in 2008.

Altogen Labs is headquartered in Austin, United States. It is registered at Austin, Texas, United States.

Dmitriy Ovcharenko is the CEO of Altogen Labs, as recorded in our data. They have also founded this company.

Altogen Labs, based in Austin, Texas, is a GLP-compliant laboratory specializing in preclinical research services. They provide xenograft animal models, pharmacology testing, and in vivo toxicology studies for pharmaceutical and academic clients. Services include stable cell line generation, RNAi delivery, and assay development to support drug efficacy and safety evaluations. The company conducts experiments using immunocompromised mice and offers detailed data reporting, focusing on cancer research and biotechnology applications.

Altogen Labs's top competitors include Dicerna Pharmaceuticals, Orna and Rejuvenate Bio.

Altogen Labs offers Xenograft Models, Stable Cell Lines, In Vivo siRNA Delivery, and Toxicology Testing.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available